Transcatheter Treatment of Mitral Regurgitation.
Angela McInerneyLuis Alfonso Marroquin DondayGabriela Tirado-ConteBreda HennesseyCarolina EspejoEduardo PozoJose Alberto de Agustín LoechesNieves GonzaloPablo SalinasIván Núñez-GilAntonio Fernández-OrtizHernan Mejía-RenteríaFernando MacayaJavier EscanedLuis Nombela-FrancoPilar Jiménez-QuevedoPublished in: Journal of clinical medicine (2022)
Mitral valve disease, and in particular mitral regurgitation, is a common clinical entity. Until recently, surgical repair and replacement were the only therapeutic options available, leaving many patients untreated mostly due to excessive surgical risk. Over the last number of years, huge strides have been made regarding percutaneous, catheter-based solutions for mitral valve disease. Transcatheter repair procedures have most commonly been used, and in recent years there has been exponential growth in the number of devices available for transcatheter mitral valve replacement. Furthermore, the evolution of these devices has resulted in both smaller delivery systems and a shift towards transeptal access, negating the need for surgical incisions. In line with these advancements, and clinical trials demonstrating promising outcomes in carefully selected cases, recent guidelines have strengthened their recommendations for these devices. It is appropriate, therefore, to now review the current transcatheter repair and replacement devices available and the evidence for their use.
Keyphrases
- mitral valve
- left atrial
- clinical trial
- left ventricular
- end stage renal disease
- ejection fraction
- newly diagnosed
- clinical practice
- chronic kidney disease
- ultrasound guided
- peritoneal dialysis
- heart failure
- body mass index
- type diabetes
- metabolic syndrome
- weight gain
- skeletal muscle
- insulin resistance
- weight loss
- phase ii
- patient reported